Diagnosis & Disease Information

Influenza vaccine efficacy, between November 23, 2018 and February 2, 2019, was 47% overall and 61% for young children.

The current available influenza vaccine may have prevented substantial cases of influenza-associated adverse outcomes.

The Food and Drug Administration (FDA) has approved the expanded use of Fluzone Quadrivalent(influenza vaccine; Sanofi Pasteur) 0.5mL to include pediatric patients aged 6 through 35 months. Both the 0.25mL and 0.5mL will be available for the upcoming 2019/20 flu season for this age range. The approval was based on findings from a Phase 4…